[Clinical study on reversal of multidrug resistance in refractory and relapsed acute leukemias by cyclosporin A].
OBJECTIVE
To explore the clinical implication of reversal of multidrug resistance (MDR) by cyclosporin A (CsA) in refractory and relapsed acute leukemias.


METHODS
The expression of p170 was assayed by immunocytochemical method (Avidin-Biotin Complex, ABC) using a monoclonal antibody JSB-1 against P-170. The P-170 positive cases were randomly divided into two groups:trial group (with CsA as revertant) and control group (without CsA), and the blood concentration of CsA was detected by HPLC.


RESULTS
The complete remission rates were 53% and 20% in trial and control group, respectively (P<0.05), and the reversing effect was positively correlated with blood concentration of CsA.


CONCLUSIONS
CsA might be a safe and effective revertant, and can be applied in the treatment of refractory and relapsed acute leukemia.
Li
X
X
First Clinical Medical College, West China University of Medical Sciences, Chengdu 610041.
Wu
J
J
Zhang
L
L
Zhu
H
H
D018435:ATP Binding Cassette Transporter, Subfamily B; D000328:Adult; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology*; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D008297:Male; D012008:Recurrence
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D006023:Glycoproteins; D016572:Cyclosporine